Drug Combination Details
| General Information of the Combination (ID: C91820) | |||||
|---|---|---|---|---|---|
| Name | Daunorubicin NP Info | + | Sunitinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute lymphoblastic leukemia
[ICD-11: 2B33]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vitro Model | MV4-11 | CVCL_0064 | Childhood acute monocytic leukemia | Homo sapiens | ||
| Ba/F3 | CVCL_0161 | Healthy | Mus musculus | |||
| MOLM-14 | CVCL_7916 | Adult acute myeloid leukemia | Homo sapiens | |||
| Experimental
Result(s) |
The addition of potent FLT3 inhibitors such as SU11248 to AML chemotherapy regimens could result in improved treatment results. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood. 2004 Dec 15;104(13):4202-9. | |||
